145 related articles for article (PubMed ID: 36338718)
1. Case report: complete remission with crizotinib in
Cao J; Yu Y; Zhou Y; Ji Q; Qian W; Jia D; Jin G; Qi Y; Li X; Li N; Li T; Fang M; Jin H
Front Oncol; 2022; 12():942258. PubMed ID: 36338718
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy alone as a method of treatment for sinonasal mucosal melanoma: A report based on six cases and a review of current opinion.
Sas-Korczynska B; Reinfuss M; Mitus JW; Pluta E; Patla A; Walasek T
Rep Pract Oncol Radiother; 2018; 23(5):402-406. PubMed ID: 30147451
[TBL] [Abstract][Full Text] [Related]
3. Sinonasal mucosal melanoma: treatment strategies and survival rates for a rare disease entity : A single center experience and review of literature.
Andrianakis A; Kiss P; Pomberger M; Wolf A; Thurnher D; Tomazic PV
Wien Klin Wochenschr; 2021 Nov; 133(21-22):1137-1147. PubMed ID: 33844113
[TBL] [Abstract][Full Text] [Related]
4. Contemporary Treatment Approaches to Sinonasal Mucosal Melanoma.
Amit M; Na'ara S; Hanna EY
Curr Oncol Rep; 2018 Feb; 20(2):10. PubMed ID: 29492677
[TBL] [Abstract][Full Text] [Related]
5. Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion.
Xie X; You M; Meng E; Wang S; Niu B; Huang W
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2561-2566. PubMed ID: 35648195
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical significance of TYRP1, ABCB5, and MMP17 in sinonasal mucosal melanoma.
Tu J; Wang J; Tang B; Zhang Z; Han M; Li M; Yu J; Shen L; Zhang M; Ye J
Cancer Biomark; 2022; 35(3):331-342. PubMed ID: 36373310
[TBL] [Abstract][Full Text] [Related]
7. Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report.
Amano Y; Kage H; Tanaka G; Sato Y; Tanaka M; Nagase T
Case Rep Oncol; 2022; 15(1):338-344. PubMed ID: 35529295
[TBL] [Abstract][Full Text] [Related]
8. Role of Adjuvant Treatment in Sinonasal Mucosal Melanoma.
Amit M; Tam S; Abdelmeguid AS; Kupferman ME; Su SY; Raza SM; DeMonte F; Hanna EY
J Neurol Surg B Skull Base; 2017 Dec; 78(6):512-518. PubMed ID: 29142805
[No Abstract] [Full Text] [Related]
9. Surgical Margin Status and Survival Following Resection of Sinonasal Mucosal Melanoma.
Elsamna ST; Ahsanuddin S; Mir GS; Sukyte-Raube D; Fang CH; Baredes S; Eloy JA
Laryngoscope; 2021 Nov; 131(11):2429-2435. PubMed ID: 33864635
[TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant therapy on survival for sinonasal mucosal melanoma.
Lai Y; Meng X; Liu Q; Lu H; Guo L; Wang S; Wang D
Acta Otolaryngol; 2020 Jan; 140(1):79-84. PubMed ID: 31755795
[No Abstract] [Full Text] [Related]
11. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Li J; Wang Q; Ge J; Tian Y; Yao W
Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.
Shu Y; Li H; Shang H; Chen J; Su X; Le W; Lei Y; Tao L; Zou C; Wu W
Onco Targets Ther; 2020; 13():10387-10391. PubMed ID: 33116618
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel
Chen AG; Chen DS; Li S; Zhao LL; Xiao MZ
Front Oncol; 2022; 12():837219. PubMed ID: 35299735
[TBL] [Abstract][Full Text] [Related]
14. Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
Dong D; Shen G; Da Y; Zhou M; Yang G; Yuan M; Chen R
Oncologist; 2020 Nov; 25(11):e1720-e1724. PubMed ID: 32652753
[TBL] [Abstract][Full Text] [Related]
15.
Cheng Y; Yang J; Wang D; Yan D
Ann Transl Med; 2022 Feb; 10(3):157. PubMed ID: 35284560
[No Abstract] [Full Text] [Related]
16. Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma.
Na'ara S; Mukherjee A; Billan S; Gil Z
Onco Targets Ther; 2020; 13():2289-2298. PubMed ID: 32214828
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel
Wei S; Hu M; Yang Y; Huang X; Li B; Ding L; Wang P
Front Oncol; 2022; 12():862008. PubMed ID: 35574423
[No Abstract] [Full Text] [Related]
19. Robotic stereotactic body radiotherapy in the treatment of sinonasal mucosal melanoma: report of four cases.
Ozyigit G; Cengiz M; Yazici G; Yildiz F; Sezen D; Yildiz D; Gurkaynak M; Zorlu F; Akyol F
Head Neck; 2013 Mar; 35(3):E69-73. PubMed ID: 22076864
[TBL] [Abstract][Full Text] [Related]
20. [Crizotinib Treatment Combined with Resection and Whole-brain Radiation Therapy
in A ROS1 Rearranged Lung Adenocarcinoma with Brain Metastasis:
Case Report and Literature Review].
Zhang M; Nie L; Zhang J
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):525-9. PubMed ID: 27561802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
